Munich researchers develop a gentle solution for weight loss!

Munich researchers develop a gentle solution for weight loss!

researchers from Munich have developed a new weight loss medication that not only has a look at fat, but also promote the preservation of muscle mass. In particular by the hype around the "weight loss injection" Ozempic, which contains the active ingredient Semaglutid and advertised by celebrities such as Kim Kardashian and Elon Musk, innovative solutions for weight loss. The drug, originally intended for reducing blood sugar in type 2 diabetes, now ensures rapid weight loss due to its side effects. Unfortunately, this often happens without medical indication, which carries potentially health risks, especially when losing muscle mass, which is particularly critical in old age.

In addition to classic weight reduction, the yo-yo effect is also a common problem in which the lost fat quickly returns after stopping the medication. This means that people who use Ozempic could fall back into old patterns. This problem is also tightened by fake recipes for Semaglutid preparations, which is a serious health risk for diabetics.

research in focus

The "Hypermet" research group led by Professor Dr. Henning Wackerhage and Professor Dr. Hanna Taipalenmäki is working on a gentler solution for weight loss. The research project is funded by the German Research Foundation (DFG) for over eight years and is divided into two phases: the first phase examines the role of muscles on metabolic processes. In the second phase, the focus is on how muscle maintenance and hypertrophy can help patients with metabolic diseases.

The results indicate that targeted muscle building protects against diabetes and at the same time promotes fat loss. A combination of muscle hypertrophy therapies with conventional weight loss medication could potentially minimize side effects. The research team also emphasizes the importance of movement and healthy nutrition as the basis for sustainable weight reduction. At the beginning of the project, strength training was carried out to bring the participants closer to the commitment to a healthy lifestyle.

new approaches to the diagnosis of obesity

The challenges in dealing with obesity are not only addressed by new medication, but also by improved diagnostic methods. Experts emphasize that the body mass index (BMI) is insufficiently as a diagnostic tool. BMI does not directly measure body fat percentage or its health effects and often leads to misdiagnoses by incorrectly considering muscular people as obese.

A new framework for the definition of obesity that distinguishes clinical and preclinical obesity is intended to improve diagnostics in the future. Clinical obesity refers to excess body fat, which leads to organ dysfunction, while preclinical obesity exists without current health problems, but is an increased risk of chronic diseases. A targeted identification of people who need treatment should be possible with improved methods such as waist circumference and direct body fat analyzes to avoid unnecessary therapies. Munich reports .

The effects of these developments are enormous. People with clinical obesity should receive evidence -based therapies to improve their organ function and quality of life. Regular monitoring and targeted advice are now considered for prevention measures to minimize the risk of future health problems.